For many children with auditory neuropathy there may be a specific molecular cause, yet the genetic testing used to determine that cause is not widely available. Decibel Therapeutics is dedicated to creating a world of connection for people with hearing and balance disorders. As part of that mission, Decibel is sponsoring the Amplify™ program to help reduce barriers to the genetic test that could deliver a precise diagnosis for patients and families. This may become especially important in the near future, as several biotech companies – including Decibel Therapeutics – are developing novel treatments designed to restore hearing in individuals with specific forms of hearing loss, including auditory neuropathy.
